The FDA has approved Opdivo® (nivolumab; Bristol Myers Squibb) for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.
The ASCO guideline provides updated recommendations for the prevention and management of chemotherapy-induced nausea and vomiting (CINV) based on the emetic risk of the treatment regimen.
Approved prostate cancer drug treatments including formulations and usual dosing.
FDA-approved oral and injectable treatment options for breast cancer.
Chemotherapeutic and biologic agents for the treatment of non-small cell lung cancer (NSCLC).
Of all types of fertility treatment examined, the only one that significantly increased the risk of cancer in children was frozen embryo transfer.
Antiemetic treatment chart including drug formulations, strengths, and usual doses for nausea/vomiting.
The FDA is working in close collaboration with global regulatory partners to evaluate the controls in place and publish guidance on preventing unacceptable levels of nitrosamine in drugs.
Biosimilars Mvasi and Kanjinti are now available in the United States.
